204 related articles for article (PubMed ID: 23348146)
21. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
[TBL] [Abstract][Full Text] [Related]
22. Mucolytics for bronchiectasis.
Wilkinson M; Sugumar K; Milan SJ; Hart A; Crockett A; Crossingham I
Cochrane Database Syst Rev; 2014 May; 2014(5):CD001289. PubMed ID: 24789119
[TBL] [Abstract][Full Text] [Related]
23. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
[TBL] [Abstract][Full Text] [Related]
24. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P; Chong J; Cates CJ
Cochrane Database Syst Rev; 2015 Jul; (7):CD001287. PubMed ID: 26222376
[TBL] [Abstract][Full Text] [Related]
25. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
[TBL] [Abstract][Full Text] [Related]
26. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
[TBL] [Abstract][Full Text] [Related]
27. N-acetylcysteine in COPD: why, how, and when?
Sanguinetti CM
Multidiscip Respir Med; 2015; 11():8. PubMed ID: 26855777
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Ascorbic Acid (Vitamin C) and/N-Acetylcysteine (NAC) Supplementation on Nutritional and Antioxidant Status of Male Chronic Obstructive Pulmonary Disease (COPD) Patients.
Pirabbasi E; Shahar S; Manaf ZA; Rajab NF; Manap RA
J Nutr Sci Vitaminol (Tokyo); 2016; 62(1):54-61. PubMed ID: 27117852
[TBL] [Abstract][Full Text] [Related]
29. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.
Criner GJ; Bourbeau J; Diekemper RL; Ouellette DR; Goodridge D; Hernandez P; Curren K; Balter MS; Bhutani M; Camp PG; Celli BR; Dechman G; Dransfield MT; Fiel SB; Foreman MG; Hanania NA; Ireland BK; Marchetti N; Marciniuk DD; Mularski RA; Ornelas J; Road JD; Stickland MK
Chest; 2015 Apr; 147(4):894-942. PubMed ID: 25321320
[TBL] [Abstract][Full Text] [Related]
30. [N-acetylcysteine reduces exacerbation frequency in COPD].
Markun S
Praxis (Bern 1994); 2013 Nov; 102(24):1495-6. PubMed ID: 24280608
[No Abstract] [Full Text] [Related]
31. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
[TBL] [Abstract][Full Text] [Related]
32. N-acetylcysteine for COPD: the evidence remains inconclusive--authors' reply.
Zheng JP; Zhong NS
Lancet Respir Med; 2014 Apr; 2(4):e3-4. PubMed ID: 24717632
[No Abstract] [Full Text] [Related]
33. N-acetylcysteine in COPD may be beneficial, but for whom?
Cazzola M; Matera MG
Lancet Respir Med; 2014 Mar; 2(3):166-7. PubMed ID: 24621673
[No Abstract] [Full Text] [Related]
34. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis.
Hansen NC; Skriver A; Brorsen-Riis L; Balsløv S; Evald T; Maltbaek N; Gunnersen G; Garsdal P; Sander P; Pedersen JZ
Respir Med; 1994 Aug; 88(7):531-5. PubMed ID: 7972979
[TBL] [Abstract][Full Text] [Related]
35. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
36. N-acetylcysteine for COPD: the evidence remains inconclusive.
Turner RD; Bothamley GH
Lancet Respir Med; 2014 Apr; 2(4):e3. PubMed ID: 24717631
[No Abstract] [Full Text] [Related]
37. Evaluation of the oxygenation index in adult respiratory failure.
Dechert RE; Park PK; Bartlett RH
J Trauma Acute Care Surg; 2014 Feb; 76(2):469-73. PubMed ID: 24458052
[TBL] [Abstract][Full Text] [Related]
38. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
[TBL] [Abstract][Full Text] [Related]
39. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.
Leuppi JD; Schuetz P; Bingisser R; Bodmer M; Briel M; Drescher T; Duerring U; Henzen C; Leibbrandt Y; Maier S; Miedinger D; Müller B; Scherr A; Schindler C; Stoeckli R; Viatte S; von Garnier C; Tamm M; Rutishauser J
JAMA; 2013 Jun; 309(21):2223-31. PubMed ID: 23695200
[TBL] [Abstract][Full Text] [Related]
40. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment.
De Flora S; Grassi C; Carati L
Eur Respir J; 1997 Jul; 10(7):1535-41. PubMed ID: 9230243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
